P013 (pertuzumab biosimilar)
/ CinnaGen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 12, 2021
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
(clinicaltrials.gov)
- P3; N=214; Completed; Sponsor: Cinnagen
Clinical • New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
1 to 1
Of
1
Go to page
1